Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors
about
Chordoma and chondrosarcoma gene profile: implications for immunotherapyA potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.Gastrointestinal stromal tumor.Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumorMedullary thyroid cancer: monitoring and therapy.Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapiesNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status.Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models.Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.Targeting Disease Persistence in Gastrointestinal Stromal TumorsRegorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.Pathology of gastrointestinal stromal tumors.Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas.Heterogeneity of kinase inhibitor resistance mechanisms in GISTMolecular characterization of pediatric gastrointestinal stromal tumors.Impact of rechallenge with imatinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib.Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor.Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entityThe GIST paradigm: lessons for other kinase-driven cancers.Gastrointestinal stromal tumors: morphological, immunohistochemical and molecular changes associated with kinase inhibitor therapy.New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future.Targeted therapies for sarcomas: new roles for the pathologist.Gastrointestinal stromal tumors: what do we know now?The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors.microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers.High CD133 expression levels in gastrointestinal stromal tumors.The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumors.Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions.Novel MIR143-NOTCH fusions in benign and malignant glomus tumors.A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors.
P2860
Q24613307-45EC7F3A-953A-4BC0-A9AF-F3E71385677DQ27851995-62E62727-7AE4-4D41-B364-3EA4CFD81531Q33489084-7E495BDC-8A37-432C-805A-959138EAECE7Q33560776-55CDB1E7-2E63-4D90-8107-F5B7CDC98EE2Q33591999-4EC4B14B-2A19-42A8-8736-1DDA4EF7E25BQ33840177-FCEEBECA-DE71-4023-B051-253EEC6C51A6Q33921067-3CD22606-662B-4F95-9BA1-E39E1D68EE21Q33988695-D7EA0514-09EA-40F8-B39D-E515215B60FEQ34029127-39172AC5-1218-4C2C-B970-4E21F5C78837Q34052411-896D1A1D-B4C4-4EF2-A160-38AFED70C9C8Q34069556-BC36D856-27BD-4B31-B340-A5F0F43D158AQ34510184-7CFC6D4A-773E-4DA6-BACC-3743A0D635B6Q34662946-4C27F23B-2FCC-419D-B0CF-7132937587A7Q35189857-CDD5BF05-1E58-4784-B7AD-C41BA4DB0104Q35555471-B42C45BD-D57B-48D8-B462-3AB947C2B53CQ35761718-6848BD87-5599-429C-BBFC-D84231244368Q35777530-595EB618-880C-4D24-91E9-B9CDD51A98B0Q35925256-52356417-56D7-4F0C-AAA4-0D48FD891750Q36129663-4E9842EA-E9C5-4444-B5A3-C88AD887111AQ36970527-30AA6B05-BF38-466F-A41C-4C28E3038935Q37058556-A6478C4A-70AA-47D5-ADAD-0A92281571B5Q37147765-69D2F2C0-8146-4CFC-8113-A01B259820BDQ37218711-4CCC17BE-F4CE-4D50-A7CD-49386660115AQ37247100-99C23C99-BA2C-476B-9234-ED051F9B8FE8Q37576843-C449AD1C-BC6F-45B1-8A96-BFFDAA394716Q37595189-A41F29B0-3393-48EA-A1FD-5DEDBDA9D1E8Q37697574-9115759E-A7CB-4A1C-879F-D8092A531DE7Q37815140-B0466C0C-2E40-416B-844F-62A547875329Q37833541-20725959-F12E-4A6D-A2D3-B5015C737963Q37850810-323356EF-4257-4DED-9CFF-CDE5350D867AQ38151788-A76CA729-09FF-4E06-8CB7-A226F97FD6F6Q38175310-641F2159-50EE-4E83-84C6-4780B01DA6D0Q38212772-830E6DDE-2441-42FE-985E-008A69163041Q38944612-3C30F15F-D3DC-4561-9713-52A8CCED5696Q39444376-72531573-7308-4CA0-A7A4-0942EA44A6A2Q39564970-B2F4ACF2-A951-4574-8A6C-B2B326C2E427Q40702293-646108F4-584D-4124-9AC2-473F34DAD47DQ41694334-5A5DF2E6-758D-49A3-9BD7-1D540C3BB007Q41867966-2840A644-D70E-478B-ACBB-EF2306DEEAF6Q43463221-7F1C65DB-17B0-48CE-B8F1-ABB275755303
P2860
Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors
description
im Januar 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 January 2007
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2007
@uk
name
Pathologic and Molecular Heter ...... astrointestinal Stromal Tumors
@en
Pathologic and Molecular Heter ...... astrointestinal Stromal Tumors
@nl
type
label
Pathologic and Molecular Heter ...... astrointestinal Stromal Tumors
@en
Pathologic and Molecular Heter ...... astrointestinal Stromal Tumors
@nl
prefLabel
Pathologic and Molecular Heter ...... astrointestinal Stromal Tumors
@en
Pathologic and Molecular Heter ...... astrointestinal Stromal Tumors
@nl
P2093
P50
P1476
Pathologic and molecular heter ...... astrointestinal stromal tumors
@en
P2093
Cristina R Antonescu
Diann DeSantis
Grace C Wong
Narasimhan P Agaram
Nicholas D Socci
Peter Besmer
Ronald P DeMatteo
Tianhua Guo
P304
P356
10.1158/1078-0432.CCR-06-1508
P407
P577
2007-01-01T00:00:00Z